I agree both of these things should be positive for the share price. My only concern is the cash flow positive has been achieved at the cost of revenue growth. That's where the proof in the pudding will be. If Catapult can keep costs reduced like the past 6 months and continue that 55% CAGR I mentioned above, then we're in for a ride.
- Forums
- ASX - By Stock
- CAT
- Catapult SaaS Valuation
Catapult SaaS Valuation, page-14
Featured News
Add CAT (ASX) to my watchlist
(20min delay)
|
|||||
Last
$3.00 |
Change
0.130(4.53%) |
Mkt cap ! $814.2M |
Open | High | Low | Value | Volume |
$2.95 | $3.23 | $2.93 | $14.49M | 4.774M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 9092 | $2.97 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$3.03 | 9042 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 50 | 2.970 |
1 | 4000 | 2.960 |
1 | 10000 | 2.950 |
1 | 340 | 2.930 |
2 | 5800 | 2.910 |
Price($) | Vol. | No. |
---|---|---|
3.060 | 7000 | 1 |
3.150 | 10000 | 1 |
3.160 | 1800 | 1 |
3.200 | 3548 | 1 |
3.250 | 6729 | 2 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
CAT (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online